<DOC>
	<DOC>NCT03047395</DOC>
	<brief_summary>The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.</brief_summary>
	<brief_title>A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis</brief_title>
	<detailed_description>This is a Phase 3, single-arm, multicenter OLE study designed to investigate the long-term safety and efficacy of 150 mg risankizumab in the treatment of moderate to severe chronic plaque psoriasis. Approximately 1900 subjects who meet the entry criteria are planned to be enrolled in this study, rolling over from the preceding Phase 2/3 studies.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subjects with a history of moderate to severe chronic plaque psoriasis, who have completed one of the preceding studies. Subjects must be candidates for prolonged open label risankizumab treatment according to investigator judgment. Premature discontinuation for any reason in the preceding study. Subjects who have developed guttate, erythrodermic, pustular or druginduced psoriasis as diagnosed by the investigator during the preceding study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
</DOC>